Integra LifeSciences Holdings Corporation $IART Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC trimmed its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 7.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,970 shares of the life sciences company’s stock after selling 1,505 shares during the period. Voya Investment Management LLC’s holdings in Integra LifeSciences were worth $439,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Arizona State Retirement System boosted its stake in Integra LifeSciences by 4.2% in the 1st quarter. Arizona State Retirement System now owns 19,894 shares of the life sciences company’s stock worth $437,000 after buying an additional 795 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in Integra LifeSciences by 4.6% in the 1st quarter. Envestnet Asset Management Inc. now owns 27,527 shares of the life sciences company’s stock worth $605,000 after buying an additional 1,204 shares during the last quarter. Sei Investments Co. boosted its stake in Integra LifeSciences by 7.4% in the 1st quarter. Sei Investments Co. now owns 20,351 shares of the life sciences company’s stock worth $451,000 after buying an additional 1,398 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Integra LifeSciences by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after buying an additional 1,975 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Integra LifeSciences by 16.3% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,811 shares of the life sciences company’s stock worth $370,000 after buying an additional 2,357 shares during the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Stock Performance

NASDAQ IART opened at $13.20 on Friday. The firm has a market capitalization of $1.03 billion, a P/E ratio of -2.02 and a beta of 1.20. Integra LifeSciences Holdings Corporation has a 1-year low of $11.06 and a 1-year high of $27.13. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.23 and a quick ratio of 0.73. The business’s 50-day simple moving average is $14.00 and its 200-day simple moving average is $14.90.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.02. The business had revenue of $415.61 million for the quarter, compared to analyst estimates of $395.06 million. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The company’s revenue was down .6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.63 EPS. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Equities analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.